Goldman analyst Tina Hou upgraded Hesai to buy from neutral, expecting the company to accelerate its global footprint and capitalize on a new product cycle.
Related Posts
JPMorgan’s top biopharma picks for 2025
The Nasdaq Biotechnology Index (NBI) has gained 6.5% this year, outpacing gains from both the S&P 500 and tech-heavy Nasdaq Composite.
Homebuyer mortgage demand drops further, as economic uncertainty roils the housing market
Mortgage rates didn’t move much last week, and neither did homebuyers who are less concerned with rates and more worried about their finances and their […]